Suomeksi
 
 
Health and quality of life after early age onset cancer

​Description of research

The Finnish nationwide healthcare registries provide a unique opportunity to study late-effects of cancer therapies. Our projects aim to recognition and alleviation of adverse effects of cancer therapies in patients still in the process of physical and psychosocial maturation.

Projects studying the immune reconstitution and viral infections in children after conventional treatment, and after stem cell transplantation for acute lymphoblastic leukemia are going on.

Evaluation on survival after Wilms’ tumor, and definition of the accuracy of serum markers for detection of abnormal renal function in children undergoing chemotherapy for malignancy have been started in collaboration with national data providers.

GCCT-project (Genetic consequences of cancer therapies at early age) is a large collaboration study with researchers in Denmark and USA to study the effects of radiation and certain chemotherapeutic agents on the health of the offspring of cancer survivors.

Bone health after early onset malignancies, Health and quality of life after early age onset brain tumors, Educational and occupational achievements after comprehensive school, and Cardiovascular morbidity and mortality following cancer treatment at early age, are nation-wide clinical and registry-based studies going on at the moment.

Physical activity and metabolic changes after childhood leukemia, and active video games to promote physical activity in children with cancer, are novel multi-disciplinary project initiations to make interventions diminishing the adverse effects of cancer therapies in childhood.

Members of the research group

Marika Grönroos, MD, PhD, post-doc
Anu Huurre, MD, PhD, post-doc
Liisa Järvelä, MD, PhD, post-doc
Andreina Kero, MD, registered doctoral candidate
Erika Gunn, MD, registered doctoral candidate,
Ritva Ahomäki, MD, registered doctoral candidate,
Lotta Hamari, Physiotherapist, registered doctoral candidate

Selected publications

Gunn ME, Lähdesmäki T, Malila N, Arola M, Grönroos M, Matomäki J, Lähteenmäki PM. Use of endocrinological and neurological medication among 5-year survivors of
young onset brain tumors. J Neurooncol. 2016 Apr 26. [Epub ahead of print] PubMedPMID: 27115743.

Kero AE, Madanat-Harjuoja LM, Järvelä LS, Malila N, Matomäki J, Lähteenmäki PM. Health conditions associated with metabolic syndrome after cancer at a young age: A nationwide register-based study. Cancer Epidemiol. 2016 Apr;41:42-9.

Kero AE, Madanat-Harjuoja LM, Järvelä LS, Malila N, Matomäki J, Lähteenmäki PM. Cardiovascular medication after cancer at a young age in Finland: A nationwide registry linkage study. Int J Cancer. 2016 Aug 1;139(3):683-90.

Gunn ME, Malila N, Lähdesmäki T, Arola M, Grönroos M, Matomäki J, Lähteenmäki PM. Late new morbidity in survivors of adolescent and young-adulthood brain
tumors in Finland: a registry-based study. Neuro Oncol. 2015 Oct;17(10):1412-8.

Ahomäki R, Gunn ME, Madanat-Harjuoja LM, Matomäki J, Malila N, Lähteenmäki PM. Late psychiatric morbidity in survivors of cancer at a young age: a nationwide registry-based study. Int J Cancer. 2015 Jul 1;137(1):183-92.

Keywords:
Tags:
 

 Docent Päivi Lähteenmäki